What a terrilble joke.
Beacuse of GSK failure to support IV relenza the US govt gave Biocryst uo to $100 million to develop this IV drug. Short needle long needle.
However you look at it its a failure. Biocryst shareprice has gone through he floor bigtime.
US taxpayers backed a dud all because of GSK lack of interest.
Its enough to make a shareholder cry.